Metastatic spread in prostate cancer patients influencing radiotherapy response

Radiotherapy and surgery are curative treatment options for localized prostate cancer (PCa) with a five-year survival rate of nearly 100%. Once PCa cells spread into distant organs, such as bone, the overall survival rate of patients drops dramatically. The metastatic cascade and organotropism of PC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Klusa, Daria (VerfasserIn) , Lohaus, Fabian (VerfasserIn) , Furesi, Giulia (VerfasserIn) , Rauner, Martina (VerfasserIn) , Benes̆ová, Martina (VerfasserIn) , Krause, Mechthild (VerfasserIn) , Kurth, Ina (VerfasserIn) , Peitzsch, Claudia (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 04 March 2021
In: Frontiers in oncology
Year: 2021, Jahrgang: 10, Pages: 1-27
ISSN:2234-943X
DOI:10.3389/fonc.2020.627379
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3389/fonc.2020.627379
Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/articles/10.3389/fonc.2020.627379/full
Volltext
Verfasserangaben:Daria Klusa, Fabian Lohaus, Giulia Furesi, Martina Rauner, Martina Benešová, Mechthild Krause, Ina Kurth and Claudia Peitzsch

MARC

LEADER 00000caa a2200000 c 4500
001 175724591X
003 DE-627
005 20230426114314.0
007 cr uuu---uuuuu
008 210506s2021 xx |||||o 00| ||eng c
024 7 |a 10.3389/fonc.2020.627379  |2 doi 
035 |a (DE-627)175724591X 
035 |a (DE-599)KXP175724591X 
035 |a (OCoLC)1341408182 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Klusa, Daria  |d 1992-  |e VerfasserIn  |0 (DE-588)123533192X  |0 (DE-627)1760365904  |4 aut 
245 1 0 |a Metastatic spread in prostate cancer patients influencing radiotherapy response  |c Daria Klusa, Fabian Lohaus, Giulia Furesi, Martina Rauner, Martina Benešová, Mechthild Krause, Ina Kurth and Claudia Peitzsch 
264 1 |c 04 March 2021 
300 |a 27 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.05.2021 
520 |a Radiotherapy and surgery are curative treatment options for localized prostate cancer (PCa) with a five-year survival rate of nearly 100%. Once PCa cells spread into distant organs, such as bone, the overall survival rate of patients drops dramatically. The metastatic cascade and organotropism of PCa cells are regulated by different cellular subtypes, organ microenvironment, and their interactions. This cross-talk leads to pre-metastatic niche formation that releases chemo-attractive factors enforcing the formation of distant metastasis. Biological characteristics of PCa metastasis impacting on metastatic sites, burden, and latency is of clinical relevance. Therefore, the implementation of modern hybrid imaging technologies into clinical routine increased the sensitivity to detect metastases at earlier stages. This enlarged the number of PCa patients diagnosed with a limited number of metastases, summarized as oligometastatic disease. These patients can be treated with androgen deprivation in combination with local-ablative radiotherapy or radiopharmaceuticals directed to metastatic sites. Unfortunately, the number of patients with disease recurrence is high due to the enormous heterogeneity within the oligometastatic patient population and the lack of available biomarkers with predictive potential for metastasis-directed radiotherapy. Another, so far unmet clinical need is the diagnosis of minimal residual disease before onset of clinical manifestation and/or early relapse after initial therapy. Here, monitoring of circulating and disseminating tumor cells in PCa patients during the course of radiotherapy may give us novel insight into how metastatic spread is influenced by radiotherapy and vice versa. In summary, this review critically compares current clinical concepts for metastatic PCa patients and discuss the implementation of recent preclinical findings improving our understanding of metastatic dissemination and radiotherapy resistance into standard of care. 
650 4 |a circulating tumor cells 
650 4 |a metastasis 
650 4 |a prostate cancer 
650 4 |a Radiopharmacy 
650 4 |a Radiotherapy 
700 1 |a Lohaus, Fabian  |e VerfasserIn  |0 (DE-588)1182057152  |0 (DE-627)1662558686  |4 aut 
700 1 |a Furesi, Giulia  |e VerfasserIn  |4 aut 
700 1 |a Rauner, Martina  |e VerfasserIn  |0 (DE-588)1208030051  |0 (DE-627)1694330931  |4 aut 
700 1 |a Benes̆ová, Martina  |e VerfasserIn  |0 (DE-588)1082788643  |0 (DE-627)847797864  |0 (DE-576)455575622  |4 aut 
700 1 |a Krause, Mechthild  |e VerfasserIn  |0 (DE-588)1184532311  |0 (DE-627)1663639779  |4 aut 
700 1 |a Kurth, Ina  |d 1979-  |e VerfasserIn  |0 (DE-588)1018535802  |0 (DE-627)690629044  |0 (DE-576)354284207  |4 aut 
700 1 |a Peitzsch, Claudia  |e VerfasserIn  |0 (DE-588)1193104408  |0 (DE-627)1671672623  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in oncology  |d Lausanne : Frontiers Media, 2011  |g 10(2021), Artikel-ID 627379, Seite 1-27  |h Online-Ressource  |w (DE-627)684965518  |w (DE-600)2649216-7  |w (DE-576)35841184X  |x 2234-943X  |7 nnas  |a Metastatic spread in prostate cancer patients influencing radiotherapy response 
773 1 8 |g volume:10  |g year:2021  |g elocationid:627379  |g pages:1-27  |g extent:27  |a Metastatic spread in prostate cancer patients influencing radiotherapy response 
856 4 0 |u https://doi.org/10.3389/fonc.2020.627379  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/articles/10.3389/fonc.2020.627379/full  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210506 
993 |a Article 
994 |a 2021 
998 |g 1018535802  |a Kurth, Ina  |m 1018535802:Kurth, Ina  |d 140000  |e 140000PK1018535802  |k 0/140000/  |p 7 
999 |a KXP-PPN175724591X  |e 3924133069 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"175724591X","title":[{"title":"Metastatic spread in prostate cancer patients influencing radiotherapy response","title_sort":"Metastatic spread in prostate cancer patients influencing radiotherapy response"}],"id":{"eki":["175724591X"],"doi":["10.3389/fonc.2020.627379"]},"note":["Gesehen am 06.05.2021"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"04 March 2021","dateIssuedKey":"2021"}],"language":["eng"],"person":[{"family":"Klusa","roleDisplay":"VerfasserIn","role":"aut","display":"Klusa, Daria","given":"Daria"},{"roleDisplay":"VerfasserIn","family":"Lohaus","role":"aut","display":"Lohaus, Fabian","given":"Fabian"},{"given":"Giulia","display":"Furesi, Giulia","role":"aut","roleDisplay":"VerfasserIn","family":"Furesi"},{"family":"Rauner","roleDisplay":"VerfasserIn","display":"Rauner, Martina","role":"aut","given":"Martina"},{"family":"Benes̆ová","roleDisplay":"VerfasserIn","role":"aut","display":"Benes̆ová, Martina","given":"Martina"},{"role":"aut","display":"Krause, Mechthild","given":"Mechthild","roleDisplay":"VerfasserIn","family":"Krause"},{"family":"Kurth","roleDisplay":"VerfasserIn","display":"Kurth, Ina","role":"aut","given":"Ina"},{"display":"Peitzsch, Claudia","role":"aut","given":"Claudia","family":"Peitzsch","roleDisplay":"VerfasserIn"}],"name":{"displayForm":["Daria Klusa, Fabian Lohaus, Giulia Furesi, Martina Rauner, Martina Benešová, Mechthild Krause, Ina Kurth and Claudia Peitzsch"]},"physDesc":[{"extent":"27 S."}],"relHost":[{"recId":"684965518","pubHistory":["2011 -"],"language":["eng"],"origin":[{"dateIssuedDisp":"2011-","publisherPlace":"Lausanne","dateIssuedKey":"2011","publisher":"Frontiers Media"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"volume":"10","text":"10(2021), Artikel-ID 627379, Seite 1-27","pages":"1-27","extent":"27","year":"2021"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Metastatic spread in prostate cancer patients influencing radiotherapy responseFrontiers in oncology","note":["Gesehen am 07.11.13"],"id":{"issn":["2234-943X"],"eki":["684965518"],"zdb":["2649216-7"]},"title":[{"title":"Frontiers in oncology","title_sort":"Frontiers in oncology"}]}]} 
SRT |a KLUSADARIAMETASTATIC0420